Oncoproteomics

Clinica Chimica Acta

Volumn 412, Issue 3-4, 2011, Pages 217-226

  Joshi, S ^a   Tiwari, A K ^b   Mondal, B ^b   Sharma, A ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Biomarkers; Cancer; Drug resistance; Matrix assisted laser desorption ionization time of flight mass spectrometry; Molecular pathways; Proteomics; Two dimensional electrophoresis

Indexed keywords

BORTEZOMIB; BOSUTINIB; BRCA1 PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DASATINIB; DOCETAXEL; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FLUOROURACIL; IMATINIB; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; STATHMIN;

BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUNG CANCER; MONITORING; MULTIPLE MYELOMA; NONHUMAN; ONCOPROTEOMICS; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEOMICS;

EID: 78650234795     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.10.002     Document Type: Review

References (112)

1. Yasui W., Oue N., Ito R., Kuraoka K., Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 2004, 95:385-392.
2. Hibbs K., Skubitz K.M., Pambuccian S.E., et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004, 165:397-414.
3. Ramagopalan S.V., Heger A., Berlanga A.J., et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010, 20:1352-1360. [Electronic publication ahead of print].
4. Gygi S., Rochon Y., Franza B.R., Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999, 19:1720-1730.
5. Chait B.T., Kent S.B. Weighing naked proteins: practical, high accuracy mass measurement of peptides and proteins. Science 1992, 257:1885-1894.
6. Dongre A.R., Eng J.K., Yates J.R. Emerging tandem-mass-spectrometry techniques for the rapid identification of proteins. Trends Biotechnol 1997, 15:418-425.
7. Gygi S., Han D.K., Gingras A.C., Sonenberg N., Aebersold R. Protein analysis by mass spectrometry and sequence database searching: tools for cancer research in the post-genomic era. Electrophoresis 1999, 20:310-319.
8. Sharma A., Khan R., Joshi S., Kumar L., Sharma M. Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk Lymphoma 2010, 51:920-927.
9. Satyam A., Singh P., Badjatia N., Seth A., Sharma A. A disproportion of T(H)1/T(H)2 cytokines with predominance of T(H)2, in urothelial carcinoma of bladder. Urol Oncol 2009, [Epub ahead of print].
10. Sharma A., Tripathi M., Satyam A., Kumar L. Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma 2009, 50:809-815.
11. Badjatia N., Satyam A., Singh P., Seth A., Sharma A. Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol 2010, 28:360-367. Epub 2009 Jan 26.
12. Sharma A., Rajappa M., Saxena A., Sharma M. Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer. Mol Diagn Ther 2007, 11:193-201.
13. Palmqvist R., Engaras B., Lindmark G., et al. Prediagnostic levels of carcinoembryonic antigen and CA 242 in colorectal cancer: a matched case-control study. Dis Colon Rectum 2003, 46:1538-1544.
14. Carriquiry L.A., Pineyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer. Dis Colon Rectum 1999, 42:921-929.
15. Catalona W., Partin A., Slawin K., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama 1998, 279:1542-1547.
16. Moonen P.M., Kiemeney L.A., Witjes J.A. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. Eur Urol 2005, 48:951-956.
17. Bassi P., De Marco V., De Lisa A., et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 2005, 75:193-200.
18. Gutiérrez Baños J.L., Rebollo Rodrigo M.H., Antolín Juárez F.M., Martín García B. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study. Urol Int 2001, 66:185-190.
19. Heicappell R., Schostak M., Müller M., Miller K. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder. Scand J Clin Lab Invest 2000, 60:275-282.
20. Boman H., Hedelin H., Holmäng S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002, 167:80-83.
21. Sardana G., Marshall J., Diamandis E.P. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem 2007, 53:429-437.
22. Rong Y., Jin D., Hou C., et al. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol 2010, 10:68. [Epub ahead of print].
23. Kim S., Cho H., Nam E.J., et al. Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer. Genes Chromosom Cancer 2010, 49:585-595.
24. Kluk B.J., Fu Y., Formolo T.A., et al. BP1, an isoform of DLX4 homeoprotein, negatively regulates BRCA1 in sporadic breast cancer. Int J Biol Sci 2010, 6:513-524.
25. Cajone F., Sherbet G.V. Stathmin is involved in S100A4-mediated regulation of cell cycle progression. Clin Exp Metastasis 1999, 17:865-871.
26. Melhem R.F., Zhu X.X., Hailat N., et al. Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J Biol Chem 1991, 266:17747-17753.
27. Jourdain L., Curmi P., Sobel A., Pantaloni D., Carlier M.F. Stathmin: a tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry 1997, 36:10817-10821.
28. Emmert-Buck M.R., Bonner R.F., Smith P.D., et al. Laser capture microdissection. Science 1996, 274:998-1001.
29. Gulmann C., Espina V., Petricoin E., et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 2005, 11:5847-5855.
30. Alhamdani M.S., Schröder C., Hoheisel J.D. Oncoproteomic profiling with antibody microarrays. Genome Med 2009, 1:68.
31. Hudelist G., Pacher-Zavisin M., Singer C.F., et al. Use of high throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res Treat 2004, 86:281-291.
32. Paweletz C.P., Charboneau L., Bichsel V.E., et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20:1981-1989.
33. Celis J.E., Wolf H., Ostergaard M. Proteomic strategies in bladder cancer. IUBMB Life 1999, 48:19-23.
34. Hickey W.F., Seiler M.W. Ultrastructural markers of colonic adenocarcinoma. Cancer 1981, 47:140-145.
35. Moertel C.G. Chemotherapy for colorectal cancer. N Engl J Med 1994, 330:1136-1142.
36. Qazi F., McGuire W.P. The treatment of epithelial ovarian cancer. CA Cancer J Clin 1995, 45:88-101.
37. Nishizuka S., Chen S.T., Gwadry F.G., et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003, 63:5243-5250.
38. Li Wei, Li Jian-Fang, Ying Qu., et al. Comparative proteomics analysis of human gastric cancer. World J Gastroenterol 2008, 14:5657-5664.
39. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
40. Cao J.N., Shafee N., Vickery L., Kaluz S., Ru N., Stanbridge E.J. Mitogen-activated protein/extracellular signal-regulated kinase kinase 1act/tubulin interaction is an important determinant of mitotic stability in cultured HT1080 human fibrosarcoma cells. Cancer Res 2010, 70:6004-6014.
41. Zhan X., Desiderio D.M. Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genet 2010, 3:13.
42. Xu B.J., Yan W., Jovanovic B., et al. Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts. Proteomics 2010, 10:2458-2470. [Epub ahead of print].
43. Krejci P., Mekikian P.B., Wilcox W.R. The fibroblast growth factors in multiple myeloma. Leukemia 2006, 20:1165-1168.
44. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149.
45. L'Hote C.G., Knowles M.A. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005, 304:417-431.
46. St-Germain J.R., Taylor P., Tong J., et al. Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci USA 2009, 106:20127-20132.
47. Duesberg P., Li R., Sachs R., Fabarius A., Upender M.B., Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist Updat 2007, 10:51-58.
48. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007, 10:59-67.
49. Sparkes R., Johnson J.A., Langlois S., et al. New molecular techniques for the prenatal detection of chromosomal aneuploidy. J Obstet Gynaecol Can 2008, 30(617-621):622-627.
50. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
51. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
52. Ferrari G., Pastorelli R., Buchi F., et al. Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. J Proteome Res 2007, 6:367-375.
53. Jinawath N., Vasoontara C., Jinawath A., et al. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS ONE 2010, 5:e11198.
54. Chauhan D., Hideshima T., Mitsiades C., Richardson P., Anderson K.C. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005, 4:686-692.
55. Zhu R., Xi H., Li Y.H., Jiang H., Zou J.F., Hou J. Establishment of a bortezomib-resistant myeloma cell line and differential proteins analysis by MALDI-OF-MS. Zhejiang Da Xue Xue Bao Yi Xue Ban 2009, 38:445-452.
56. Lee S., Choi H., Kim E., et al. Melphalan inhibits adenoma development through modulating the expression of K-ras-specific markers in K-ras Tg mice. Int J Oncol 2010, 37:219-228.
57. Holmes F.A., Walters R.S., Theriault R.L., et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83:1797-1805.
58. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
59. Murphy W.K., Fossella F.V., Winn R.J., et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993, 85:384-388.
60. McClung J.K., Jupe E.R., Liu X.T., Dell'Orco R.T. Prohibitin: potential role in senescence, development, and tumor suppression. Exp Gerontol 1995, 30:99-124.
61. Mishra S., Murphy L.C., Nyomba B.L., Murphy L.J. Prohibitin: a potential target for new therapeutics. Trends Mol Med 2005, 11:192-197.
62. Patel N., Chatterjee S.K., Vrbanac V., et al. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc Natl Acad Sci USA 2010, 107:2503-2508.
63. Bantscheff M., Eberhard D., Abraham Y., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25:1035-1044.
64. Yim E.K., Lee K.H., Bae J.S., Namkoong S.E., Um S.J., Park J.S. Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell Biol 2004, 23:769-776.
65. Lee K.H., Yim E.K., Kim C.J., Namkoong S.E., Um S.J., Park J.S. Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol 2005, 98:45-53.
66. Altun M., Galardy P.J., Shringarpure R., et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005, 65:7896-7901.
67. Pietrowska M., Polanska J., Marczak L., et al. Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer. J Transl Med 2010, 8:66. [Epub ahead of print].
68. Heike Y., Hosokawa M., Osumi S., et al. Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res 2005, 25:1197-1203.
69. Conrads T.P., Hood B.L., Issaq H.J., Veenstra T.D. Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool. Mol Diagn 2004, 8:77-85.
70. Posadas E.M., Simpkins F., Liotta L.A., MacDonald C., Kohn E.C. Proteomic analysis for the early detection and rational treatment of cancer-realistic hope?. Ann Oncol 2005, 16:16-22.
71. Cho W.C.S. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007, 6:25.
72. Azad N.S., Rasool N., Annunziata C.M., Minasian L., Whiteley G., Kohn E.C. Proteomics in clinical trials and practice. Mol Cell Proteomics 2006, 5:1819-1829.
73. Solassol J., Jacot W., Lhermitte L., Boulle N., Maudelonde T., Mangé A. Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics 2006, 3:311-320.
74. Palmblad M., Tiss A., Cramer R. Mass spectrometry in clinical proteomics - from the present to the future. Proteomics Clin Appl 2009, 3:6-17.
75. Kusnezow W., Jacob A., Walijew A., Diehl F., Hoheisel J.D. Antibody microarrays: an evaluation of production parameters. Proteomics 2003, 3:254-264.
76. Kusnezow W., Hoheisel J.D. Antibody microarrays: promises and problems. Biotechniques 2002, 14-23. Suppl.
77. Sittampalam G.S., Smith W.C., Miyakawa T.W., Smith D.R., McMorris C. Application of experimental design techniques to optimize a competitive ELISA. J Immunol Meth 1996, 190:151-161.
78. Jeronimo C., Nomoto S., Caballero O.L., et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001, 20:5195-5198.
79. Kagan J., Srivastava S. Mitochondria as a target for early detection and diagnosis of cancer. Crit Rev Clin Lab Sci 2005, 42:453-472.
80. Verma M., Kagan J., Sidransky D., Srivastava S. Proteomic analysis of cancer-cell mitochondria. Nat Rev Cancer 2003, 3:789-795.
81. Singh K.K., Russell J., Sigala B., Zhang T., Williams J., Keshav K.F. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 1999, 18:6641-6646.
82. Weissig V., Boddapati S.V., D'Souza G.G.M., Cheng S.M. Targeting of low-molecular weight drugs to mammalian mitochondria. Drug Des Rev 2004, 1:15-28.
83. Tiacci E., Orvietani P.L., Bigerna B., et al. Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells. J Proteome Res 2006, 5:2389-2395.
84. Wan W.H., Fortuna M.B., Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Meth 1987, 103:121-129.
85. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847.
86. Camp R.L., Neumeister V., Rimm D.L. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008, 26:5630-5637.
87. Gavin A.C., Bösche M., Krause R., et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 2002, 415:141-147.
88. Zheng Y.G., Wu J., Chen Z., Goodman M. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med Res Rev 2008, 28:645-687.
89. Bantscheff M., Eberhard D., Abraham Y., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25:1035-1044.
90. Bouwmeester T., Bauch A., Ruffner H., et al. A physical and functional map of the human TNF-alpha/NF-kappaB signal transduction pathway. Nat Cell Biol 2004, 6:97-105.
91. Issaq H., Veenstra T. Two-dimensional polyacrylamide gel electrophoresis (2DPAGE): advances and perspectives. Biotechniques 2008, 44:697-708.
92. Horváth C.S., Preiss B.A., Lipsky S.R. Fast liquid chromatography. Investigation of operating parameters and the separation of nucleotides on pellicular ion exchangers. Anal Chem 1967, 39:1422-1428.
93. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17:994-999.
94. Thompson A., Schäfer J., Kuhn K., et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 2003, 75:1895-1904.
95. Jiang H., English A.M. Quantitative analysis of the yeast proteome by incorporation of isotopically labeled leucine. J Proteome Res 2002, 1:345-350.
96. Ong S.E., Blagoev B., Kratchmarova I., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386.
97. Henzel W.J., Billeci T.M., Stults J.T., Wong S.C., Grimley C., Wattanabe C. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci USA 1993, 90:5011-5015.
98. Fenn J.B., Mann M., Meng C.K., Wong S.F., Whitehouse C.M. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989, 246:64-71.
99. Fields S., Song O. A novel genetic system to detect proteinprotein interactions. Nature 1989, 340:245-246.
100. Fields S. High-throughput two-hybrid analysis: the promise and the peril. FEBS Lett 2005, 272:5391-5399.
101. McCraith S., Holtzman T., Moss B., Fields S. Genome-wide analysis of vaccinia virus protein-protein interactions. Proc Natl Acad Sci USA 2000, 97:4879-4884.
102. Uetz P., Giot L., Cagney G., et al. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 2000, 403:623-627.
103. Förster T. Transfer mechanisms of electronic excitation. Discuss Faraday Soc 1959, 27:7-17.
104. Heim R., Cubitt A.B., Tsien R.Y. Improved green fluorescence. Nature 1995, 373:663-664.
105. Michnick S.W. Protein fragment complementation strategies for biochemical network mapping. Curr Opin Biotechnol 2003, 14:610-617.
106. Michnick S.W., Remy I., Campbell-Valois F.X., Vallee-Belisle A., Pelletier J.N. Detection of protein-protein interactions by protein fragment complementation strategies. Meth Enzymol 2000, 328:208-231.
107. Rigaut G., Shevchenko A., Rutz B., Wilm M., Mann M., Séraphin B. A generic protein purification method for protein complex characterization and proteome exploration. Nat Biotechnol 1999, 17:1030-1032.
108. Spurrier B., Spurrier B., Ramalingam S., Nishizuka S. Reverse-phase protein microarrays for cell signaling analysis. Nat Protoc 2008, 3:1796-1808.
109. Sheehan K.M., Calvert V.S., Kay E.W., et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005, 4:346-355.
110. Hultschig C., Kreutzberger J., Seitz H., Konthur Z., Büssow K., Lehrach H. Recent advances of protein microarrays. Curr Opin Chem Biol 2006, 10:4-10.
111. Rivas L.A., García-Villadangos M., Moreno-Paz M., Cruz-Gil P., Gómez-Elvira J., Parro V. A 200-antibody microarray biochip for environmental monitoring: searching for universal microbial biomarkers through immunoprofiling. Anal Chem 2008, 80:7970-7979.
112. Collas P. The current state of chromatin immunoprecipitation. Mol Biotechnol 2010, 45:87-100.